Previous 10 | Next 10 |
WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that it has granted an induceme...
WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that Wildon Farwell, M.D., ...
2024-03-25 07:54:55 ET More on Dyne Therapeutics Dyne: H2 2024 Muscle Disease Data Could Boost Value Dyne Therapeutics: An Updated Analysis Assessing Dyne Therapeutics' Muscular Dystrophy Data: Early Promise, Caution Needed Dyne Therapeutics GAAP EPS of -$1.0...
- John Cox, Industry Leader with Global Experience in Rare Disease Commercialization, Joins Dyne as President and CEO - WALTHAM, Mass., March 25, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative li...
WALTHAM, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to ...
2024-03-05 14:48:29 ET Summary Dyne Therapeutics, Inc. results from the phase 1/2 ACHIEVE study, using DYNE-101 for the treatment of patients with Myotonic Dystrophy Type 1, expected in H2 2024. The Myotonic Dystrophy Type 1 treatment market is expected to reach $2.78 billion by 2...
2024-03-05 07:37:47 ET More on Dyne Therapeutics Dyne Therapeutics: An Updated Analysis Assessing Dyne Therapeutics' Muscular Dystrophy Data: Early Promise, Caution Needed Dyne Therapeutics jumps amid report of takeover interest Dyne Therapeutics prices stock...
- Positive Initial Clinical Data from ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients Demonstrated Proof-of-Concept, Validating the Promise of the FORCE™ Platform and Targeted Delivery to Muscle - - Strengthened Balance Sheet with $345 Million Public O...
2024-02-21 14:49:26 ET Summary Dyne Therapeutics, Inc. stock has rebounded strongly after positive news from its rival's program and good data readout from its own clinical trials. The company's candidates are developed using its FORCE platform, which utilizes muscle cells' own re...
2024-02-19 18:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
News, Short Squeeze, Breakout and More Instantly...
2024-05-21 08:00:14 ET Keay Nakae from Chardan Capital issued a price target of $42.00 for DYN on 2024-05-21 07:09:00. The adjusted price target was set to $42.00. At the time of the announcement, DYN was trading at $35.38. The overall price target consensus is at $34.00...
Monday, Dyne Therapeutics Inc (NASDAQ:DYN) released clinical data from its ongoing Phase 1/2 ACHIEVE trial of DYNE-101 in patients with m...
A look at the top 10 most actives in the United States Crown Electrokinetics Corp. (CRKN) rose 16.4% to $0.199 on volume of 720,586,242 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 74.8% to $1.8 on volume of 682,362,254 shares Pineapple Energy Inc. (PEGY) rose 80.3% to $0.1...